Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

Bibliographic Details
Main Authors:	Zhenyu Wei, Jiayu Xu, Chengkui Zhao, Min Zhang, Nan Xu, Liqing Kang, Xiaoyan Lou, Lei Yu, Weixing Feng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Immunology
Subjects:	CAR-T cell therapy cytokine release syndrome (CRS) biomarker prediction decision tree
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1379325/full

Similar Items

Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells
by: Zhenyu Wei, et al.
Published: (2023-10-01)

PrCRS: a prediction model of severe CRS in CAR-T therapy based on transfer learning
by: Zhenyu Wei, et al.
Published: (2024-05-01)

Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk
by: Zhenyu Wei, et al.
Published: (2022-09-01)

Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes
by: Liqing Kang, et al.
Published: (2020-06-01)

A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023
by: Huimin Li, et al.
Published: (2023-12-01)

Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS
by: Chiara Masucci, et al.
Published: (2023-06-01)

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
by: Tim Lakomy, et al.
Published: (2023-02-01)

Influence of CAR T-cell therapy associated complications
by: Mohammad Mussab Umair, et al.
Published: (2025-02-01)

Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy
by: Baitao Dou, et al.
Published: (2024-01-01)

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
by: Joseph W. Fischer, et al.
Published: (2021-06-01)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
by: Zhenguang Wang, et al.
Published: (2018-01-01)

Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy
by: Shohei Moriyama, et al.
Published: (2022-03-01)

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis
by: Jingming Luo, et al.
Published: (2024-06-01)

EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
by: Felix Korell, et al.
Published: (2022-04-01)

The first case of multiple myeloma treated with ASCT followed by Anti-BCMA CAR-T cells using retrovirus vector: A case report
by: Liqiong Liu, et al.
Published: (2024-09-01)

Case report: CAR-T cell therapy-induced cardiac tamponade
by: Sacha Sarfati, et al.
Published: (2023-03-01)

Soluble factors released by peripheral blood-derived CAR-NK cells cause bystander myeloid cell activation
by: Supreet Khanal, et al.
Published: (2024-12-01)

Etiological analysis of infection after CRS + HIPEC in patients with PMP
by: Rui Yang, et al.
Published: (2023-09-01)

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
by: Paolo F. Caimi, et al.
Published: (2021-10-01)

Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells
by: Ke Zeng, et al.
Published: (2023-07-01)

Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin’s lymphoma
by: David G. Frame, et al.
Published: (2024-06-01)

The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy—Are They Biomarkers of Therapy-Related Toxicities?
by: Paweł Marschollek, et al.
Published: (2024-07-01)

Next generations of CAR-T cells - new therapeutic opportunities in hematology?
by: Jaromir Tomasik, et al.
Published: (2022-10-01)

Reusable and robust fuzzy extractor for CRS-dependent sources
by: Yucheng Ma, et al.
Published: (2025-01-01)

Increased prevalence of CFTR variants and susceptibility to CRS: A real-world study based on Chinese children
by: Yang Han, et al.
Published: (2024-04-01)

A score-based method of immune status evaluation for healthy individuals with complete blood cell counts
by: Min Zhang, et al.
Published: (2023-12-01)

The NHS Care Record Service (NHS CRS): recommendations from the literature on successful implementation and adoption
by: Kathrin Cresswell, et al.
Published: (2009-09-01)

CAR T-cells for T-cell acute lymphoblastic leukemia
by: Marie Emilie Dourthe, et al.
Published: (2024-06-01)

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
by: Xinyi Xiao, et al.
Published: (2021-11-01)

IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines
by: Zhiliang Jia, et al.
Published: (2022-09-01)

Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects
by: Zhaozhao Chen, et al.
Published: (2024-01-01)

INDEPSO-ISPSM consensus on peritoneal malignancies – Enhanced recovery after surgery in cytoreductive surgery (CRS) with/without hyperthermic intraperitoneal chemotherapy (HIPEC)
by: Geetu Prakash Bhandoria, et al.
Published: (2025-02-01)

Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release
by: Ang Zhang, et al.
Published: (2021-10-01)

Naturally selected CD7-directed CAR-T bridging allo-HSCT in refractory acute myeloid leukemia: a case report and review
by: Xuan Liu, et al.
Published: (2024-10-01)

Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
by: Zhou S, et al.
Published: (2021-03-01)

Rubella Seroprevalence Boost in the Pediatric and Adolescent Population of Florence (Italy) as a Preventive Strategy for Congenital Rubella Syndrome (CRS)
by: Beatrice Zanella, et al.
Published: (2020-10-01)

Genetic Susceptibility in Endothelial Injury Syndromes after Hematopoietic Cell Transplantation and Other Cellular Therapies: Climbing a Steep Hill
by: Paschalis Evangelidis, et al.
Published: (2024-05-01)

Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models
by: Arezoo Jamali, et al.
Published: (2024-03-01)

Implementation of ERAS guidelines in patients undergoing CRS and HIPEC: need for multicentre trial
by: Iavazzo Christos, et al.
Published: (2023-12-01)

Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients
by: Núria Vidal Robau, et al.
Published: (2022-01-01)